Daybue is owned by Acadia Pharms Inc.
Daybue contains Trofinetide.
Daybue has a total of 2 drug patents out of which 0 drug patents have expired.
Daybue was authorised for market use on 10 March, 2023.
Daybue is available in solution;oral dosage forms.
Daybue can be used as treatment of rett syndrome or a symptom thereof.
Drug patent challenges can be filed against Daybue from 2027-03-11.
The generics of Daybue are possible to be released after 03 August, 2040.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US11370755||ACADIA PHARMS INC||Compositions of trofinetide|| |
(17 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9212204||ACADIA PHARMS INC||Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid|| |
(8 years from now)
|Orphan Drug Exclusivity (ODE)||Mar 10, 2030|
|New Chemical Entity Exclusivity (NCE)||Mar 10, 2028|
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 2027-03-11
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic